Laboratory Products
Inventory Management
Feb 19 2010
NanoSight announce that UK biotechnology company, Henderson Morley plc, is using nanoparticle tracking analysis (NTA) to quantify virus particle number for batch to batch control.
Henderson Morley is developing an exciting pipeline of anti-viral drugs and vaccines and biological products to fight a wide range of diseases in humans and animals. Their lead vaccine technology platform uses PREPS
and L-particles, which are virus-like particles derived from Human Herpes Virus 1 (HHV-1). These particles have the same size as herpes viruses, but do not contain viral DNA and are therefore sterile. Conventional viral
quantification relies on the infectious yield of viruses but as these particles do not replicate, an alternate quantification technique had to be found.
Previously the only way to quantify particle number relied on less accurate protein concentration measurements. The company had also used costly and time consuming electron microscopy through a local university,
and although this gave good results, it was not practical for batch to batch quantification of the L and PREPS particles.
Several benefits have been produced since the purchase of the NanoSight system. Henderson Morley’s Principal Scientist, Dr Chris Hartley, has been impressed with the speed and ease of use. “The reproducibility of results providing both particle size and particle counts in real time has been excellent. Also negligible on-going and running costs have meant that the NanoSight instrument is proving to be a very cost effective solution.”
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 11 2024 Bangkok, Thailand